Clearside Biomedical, Inc. (CLSD) Stock Analysis & Investment Frameworks
Clearside Biomedical, Inc. (CLSD) stock analysis on Invetso. Review Clearside Biomedical, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Clearside Biomedical, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Clearside Biomedical, Inc. Key Financial Metrics
- Market Cap: $2.15M
- Revenue: $1.66M
- ROE: 20.39%
- ROIC: -114.62%
- Dividend Yield: N/A
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.